Exelixis, Inc. (FRA:EX9)

Germany · Delayed Price · Currency is EUR

36.99

-0.02 (-0.05%)

Last updated: Dec 3, 2025, 8:17 AM CET

8.76% (1Y)

Market Cap	10.24B
Revenue (ttm)	1.95B
Net Income (ttm)	577.78M
Shares Out	n/a
EPS (ttm)	2.03
PE Ratio	17.73
Forward PE	13.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	240
Open	36.99
Previous Close	37.01
Day's Range	36.99 - 36.99
52-Week Range	29.41 - 44.40
Beta	n/a
RSI	55.14
Earnings Date	Feb 11, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1994

Employees 1,147

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol EX9

Full Company Profile

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD Financial Statements

News

There is no news available yet.